Thetis Pharmaceuticals

Thetis Pharmaceuticals LLC is a biopharmaceutical company dedicated to developing novel small-molecule drugs for the treatment of inflammatory diseases. Our lead candidate is a novel Resolvin E1 small-molecule therapy (TP-317), which is being developed as a treatment for solid tumor cancers and inflammatory bowel disease (IBD). TP-317 offers a differentiated therapeutic strategy that harnesses natural resolution mechanisms without suppressing the immune system. Based on Phase 1 clinical trials demonstrating that oral RvE1 has a favorable safety and tolerability profile in healthy volunteers, Thetis plans to rapidly advance TP-317 into clinical development in 2022.